MedicineImmunologyImmunopharmacologyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationGraft-versus-host DiseaseTransplant ImmunopharmacologyGraft Versus Host Disease ModulationGraft-versus-host Disease Pathophysiology
Severe graft-versus-host disease was induced by transplantation of ACI rat bone marrow and spleen cells into irradiated Lewis rat recipients. Treatment with FK 506 or cyclosporine A (CsA) was started after clinical and histologic evidence of acute GVHD was present. A 14-day course of FK 506 at 1.0 mg/kg/day could rescue 100% of the animals suffering from GVHD. In contrast only one half of the animals treated with CsA at a high dose of 25 mg/kg/day recovered. After cessation of immunosuppressive therapy, FK 506-treated animals displayed a marked prolonged disease-free interval as compared to CsA-treated bone marrow recipients. Recurrence of the disease in these animals could be prevented when FK 506 treatment was continued after the induction period with a low maintenance dose of 0.1 mg/kg/day every other day.
23
FK 506 FOR LIVER, KIDNEY, AND PANCREAS TRANSPLANTATION
ThomasE. Starzl, John J. Fung, Raman Venkataramman et al. · The Lancet · 1989 · 1.1K citations
Medicine, Pharmacokinetics, Surgery +12